利迈先治疗儿童幽门螺杆菌相关性胃、十二指肠疾病的疗效评价

Evaluation of Therapeutic Effect of Limaixian in Treating HP-related Gastroduodenopathy of Childhood

目的 :观察利迈先在儿童幽门螺杆菌相关性胃、十二指肠疾病的疗效 ,探讨其在三联短程疗法中的地位。方法 :153例经胃镜活检或C13-UBT检查 ,确诊为幽门螺杆菌 (HP)相关性胃、十二指肠疾病 ,随机分成A、B、C3组 ,采用以奥美拉唑为主的三联疗法。A组用奥美拉唑0 8mg/(kg·d)联合甲硝唑20mg/(kg·d)、羟氨苄青霉素40mg/(kg·d)。B组用奥美拉唑联合甲硝唑、克拉仙15mg/(kg·d)。C组用奥美拉唑联合甲硝唑、利迈先15mg/(kg·d)。治疗2wk ,停药4wk以后作胃镜检查或C13-UBT检查。结果 :(1)HP根除率A组62 7 % ,B组92 1 % ,C组94 1 %。B、C组根除率均明显高于A组 ,3组相比有显著性差异 ,X2=31 8 ,P<0 01。B、C组之间无明显差异。(2)治疗后1wk、2wk疼痛缓解率B、C组均明显高于A组 ,X2=19 3 ,P<0 05 ,而B、C组之间无明显差异。结论 :利迈先三联短程疗法抗HP感染 ,疗效明显好于羟氨苄青霉素 ,疗效可与克拉仙相媲美 ,且价格便宜 。

OBJECTIVE:To observe the therapeutic effect of limaixian in treating Helicobacterium pyloricus(HP)-related gastroduodenopathy of childhood and evaluate its role playing in triple short-term therapeutic scheme(TS scheme) METHODS:153 patients,who had definitely been diagnosed as HP-related gastroduodenopathy by gastroscopy or 13 C-UBT,were randomly divided into three groups(A,B,C)receiving ST scheme(omeprazole as the main drug) Group A:omeprazole 0 8mg/(kg·d),metronidazole 20mg/(kg·d) and amoxycillin 40mg/(kg·d);Group B omeprazole,metronidazole and klacid 15mg/(kg·d);Group C:omeprazole,metronidazole and limaixian 15mg/(kg·d) Therapeutic course was 2 wks and gastroscopy or 13C-UBT were carried out 4 wks after discontinuation of drugs RESULTS:(1)HP eradication rates of group A,B and C were 62 7%,92 1% and 94.1% respectively.The rates of group B,C were higher than that of group A.There were significant differences among three groups(X2=31.8,P<0.01).Group B showed no significant different with group C.(2) The remission rates of pain of group B and C were markedly higher than that of group A one and two wks after treatment (X2=19.3,P<0.05),there was no significant difference between group B and C.CONCLUSION:As an anti-HP infection agent in TS scheme,limaixian is better than amoxycillin in therapeutic effect.Limaixian is comparable with imported klacid and inexpensive in price,it can be used as the first choice antibiotic in TS scheme.